Alan Houghton Selected Research

g209-2M melanoma peptide

1/2006

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan Houghton Research Topics

Disease

5	Neoplasms (Cancer) 07/2008 - 01/2006
5	Melanoma (Melanoma, Malignant) 06/2008 - 12/2002
4	Neoplasm Metastasis (Metastasis) 06/2008 - 01/2003
1	Vaccinia 11/2008
1	Virus Diseases (Viral Diseases) 11/2008
1	Infections 11/2008
1	Cutaneous Malignant Melanoma 03/2007
1	Leukemia 01/2006

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 06/2008 - 12/2002
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2008 - 05/2004
1	Antiviral Agents (Antivirals)IBA 11/2008
1	Interleukin-6 (Interleukin 6)IBA 11/2008
1	Interferon-betaIBA 11/2008
1	Tumor Suppressor Protein p14ARF (p14ARF)IBA 06/2008
1	Cyclin-Dependent Kinase Inhibitor p16IBA 06/2008
1	Matrix Metalloproteinases (MMPs)IBA 10/2007
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 03/2007
1	g209-2M melanoma peptideIBA 01/2006
1	EpitopesIBA 01/2006
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2006
1	Interleukin-2 (IL2)IBA 01/2006
1	Peptides (Polypeptides)IBA 01/2006
1	VaccinesIBA 01/2006
1	Oxidoreductases (Dehydrogenase)IBA 01/2003

Therapy/Procedure

1	Ligation 06/2008
1	Therapeutics 01/2006